BFM
ANIK icon

Boothbay Fund Management’s Anika Therapeutics ANIK Stock Holding History

Boothbay Fund Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Buy
529,640
+137
+0% +$2.03K 0.1% 218
2026
Q1 		$7.68M Sell
529,503
-5,004
-0.9% -$58.1K 0.1% 195
2025
Q4 		$5.14M Sell
534,507
-5,135
-1% -$49.2K 0.08% 284
2025
Q3 		$5.07M Buy
539,642
+10,139
+2% +$96.8K 0.07% 314
2025
Q2 		$5.6M Hold
529,503
– – 0.11% 266
2025
Q1 		$7.96M Hold
529,503
– – 0.21% 122
2024
Q4 		$8.72M Buy
529,503
+25,665
+5% +$506K 0.21% 125
2024
Q3 		$12.4M Buy
503,838
+1,888
+0.4% +$48.9K 0.28% 56
2024
Q2 		$12.7M Sell
501,950
-224
-0% -$5.8K 0.3% 47
2024
Q1 		$12.8M Sell
502,174
-7,348
-1% -$178K 0.25% 55
2023
Q4 		$11.5M Sell
509,522
-108,080
-17% -$2.24M 0.29% 52
2023
Q3 		$11.5M Buy
617,602
+128,975
+26% +$2.67M 0.27% 65
2023
Q2 		$12.7M Buy
488,627
+1,630
+0.3% +$43.6K 0.28% 46
2023
Q1 		$14M Buy
486,997
+119,487
+33% +$3.56M 0.29% 42
2022
Q4 		$10.9M Buy
367,510
+197,510
+116% +$5.62M 0.25% 56
2022
Q3 		$4.05M Buy
+170,000
New +$3.91M 0.1% 256
2016
Q4 		– Sell
-4,298
Closed -$206K – 744
2016
Q3 		$206K Buy
+4,298
New +$212K 0.04% 549

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Boothbay Fund Management's ANIK Position: Q2 2026 in Review

Boothbay Fund Management increased its Anika Therapeutics (ANIK) stake by 0.03% in Q2 2026, buying an estimated $2.03K and bringing the position to 529,640 shares worth $7.75M. The position accounts for 0.1% of the portfolio, ranked #218.

Boothbay Fund Management first reported a position in ANIK in Q3 2016 and has held it in 17 quarters since. The position peaked at $14M in Q1 2023. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • Boothbay Fund Management held 529,640 shares of Anika Therapeutics worth $7.75M as of Q2 2026.
  • Boothbay Fund Management bought 137 Anika Therapeutics shares in Q2 2026, an estimated $2.03K.
  • Anika Therapeutics made up 0.1% of Boothbay Fund Management's portfolio in Q2 2026, its #218 holding.
  • Boothbay Fund Management first reported a position in Anika Therapeutics in Q3 2016 and has held it in 17 quarters since.
  • Boothbay Fund Management's Anika Therapeutics position peaked at $14M in Q1 2023.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.